ΕΛΓΕΚΑ Α.Ε.
Business development in the mother company and in the group.
ELGEKA S.A. would like to notify the investing public that today, on the 23rd of July 2009, paid in cash 1.558.190 euros in order to participate in the capital increase of two subsidiaries "MEDIHELM PHARMAC.WHOLESALE STORE S.A." and "SAMBROOK PHARMACEUTICAL S.A.".
More specifically, "MEDIHELM PHARMAC.WHOLESALE STORE S.A." decided on 30 June 2009 the reduction of its Share Capital by 846.000 euros through a reduction in the par value of the share from 40 euros to 20 euros in order to capitalize the losses occurred at previous results, and a parallel increase of the Share Capital by 1.502.000 euros through the issuance of 75.100 new common shares, at a par value of 20 euros each. After the above decision the Share Capital will amount to 2.348.000 euros divided into 117.400 common shares, at a par value 20 euros each.
The other shareholder declared her intention not to participate to the above mentioned increase of Share Capital of "MEDIHELM PHARMAC.WHOLESALE STORE S.A.", so ELGEKA S.A. has covered in whole the Share Capital Increase by 1.502.000 euros and will own 96,95% from 91,54% which was its former participation.
Furthermore, the company "SAMBROOK PHARMACEUTICAL S.A." decided on 30 June 2009 the increase of its Share Capital by 61.500 euros through the issuance of 4.100 new common shares, at a par value of 15 euros each. After the above decision, the Share Capital of "SAMBROOK PHARMACEUTICAL S.A." will amount to 1.014.000 euros divided into 67.600 common shares at a par value 15 euros each.
ELGEKA S.A. has paid in cash the amount of 56.190 euros in order to participate in the aforementioned share capital increase of "SAMBROOK PHARMACEUTICAL S.A.", proportionally to its participation rate which is equal to 91,34%.
More specifically, "MEDIHELM PHARMAC.WHOLESALE STORE S.A." decided on 30 June 2009 the reduction of its Share Capital by 846.000 euros through a reduction in the par value of the share from 40 euros to 20 euros in order to capitalize the losses occurred at previous results, and a parallel increase of the Share Capital by 1.502.000 euros through the issuance of 75.100 new common shares, at a par value of 20 euros each. After the above decision the Share Capital will amount to 2.348.000 euros divided into 117.400 common shares, at a par value 20 euros each.
The other shareholder declared her intention not to participate to the above mentioned increase of Share Capital of "MEDIHELM PHARMAC.WHOLESALE STORE S.A.", so ELGEKA S.A. has covered in whole the Share Capital Increase by 1.502.000 euros and will own 96,95% from 91,54% which was its former participation.
Furthermore, the company "SAMBROOK PHARMACEUTICAL S.A." decided on 30 June 2009 the increase of its Share Capital by 61.500 euros through the issuance of 4.100 new common shares, at a par value of 15 euros each. After the above decision, the Share Capital of "SAMBROOK PHARMACEUTICAL S.A." will amount to 1.014.000 euros divided into 67.600 common shares at a par value 15 euros each.
ELGEKA S.A. has paid in cash the amount of 56.190 euros in order to participate in the aforementioned share capital increase of "SAMBROOK PHARMACEUTICAL S.A.", proportionally to its participation rate which is equal to 91,34%.